Duolingo Inc vs Zoetis Inc — how do they compare? Duolingo Inc trades at $150.02 (market cap $7.08B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.3× Duolingo Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Zoetis Inc for 70 Days on average.
| DUOL | ZTS | |
|---|---|---|
Market Cap | $7.08B | $30.20B |
Volume | 729,171 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $341.08 | $147.53 |
52-Week Low | $90.03 | $69.09 |
Typical Hold Time | 137 Days | 70 Days |
Enterprise Value | $5.85B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $149.92, down 1.19% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $0.66 versus $0.60, continuing a pattern of earnings outperformance. Revenue growth remains robust at 39% year-over-year for 2025, reaching $1.04 billion, while maintaining exceptional profitability with a 35.87% net income margin. Technical indicators show a bullish moving average configuration despite neutral oscillators.
Duolingo presents a compelling growth story with accelerating revenue expansion and industry-leading margins, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share sales totaling $4.3 million in September 2026 and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, suggesting the stock may be fairly valued near current levels despite strong operational performance.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →